PIM1 and glioblastoma: Although PIM inhibitor SGI-1776 was withdrawn from clinical trials due to cardiac toxicity, we have used this small molecule as proof-of-concept to demonstrate the important role of PIM kinases as mediators of TRAIL resistance in GBM cells.